Everything You Need to Know about Cablivi Prescribing Information
Do you know what Cablivi is? If you are a healthcare professional who is involved in the care of patients with acquired thrombotic thrombocytopenic purpura (aTTP), you may have already come across it.
Cablivi, also known as caplacizumab, is a prescription medication used to treat aTTP. This condition is characterized by the formation of blood clots in small blood vessels throughout the body, leading to low platelet count and systemic organ damage. Cablivi works by inhibiting the interaction between von Willebrand factor (vWF) and platelets, preventing the formation of blood clots.
Before prescribing Cablivi to your patients, it is important to have a thorough understanding of its prescribing information. Here are some key facts you need to know:
Indication and Dosage
Cablivi is indicated for the treatment of adult patients with aTTP in combination with plasma exchange and immunosuppressive therapy. The recommended dosage is 10 mg intravenously once daily for the initial treatment of aTTP, followed by 10 mg once daily for 30 days after the last daily plasma exchange.
Contraindications
Cablivi is contraindicated in patients with a history of severe hypersensitivity reactions to caplacizumab or any of its components. It should also not be used in patients with active major bleeding.
Adverse Reactions
The most common adverse reactions observed with Cablivi include epistaxis (nosebleeds), gingival bleeding (bleeding gums), and bruising. Other adverse reactions include headache, back pain, and elevated liver enzymes. Serious adverse reactions, such as severe bleeding, have also been reported.
Drug Interactions
Cablivi may increase the risk of bleeding when used concomitantly with anticoagulant or antiplatelet agents. Close monitoring of coagulation parameters is required when Cablivi is used with these medications.
Pregnancy and Lactation
There are no adequate and well-controlled studies of Cablivi in pregnant women. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is also unknown whether Cablivi is excreted in human milk, and caution should be exercised when administering Cablivi to lactating women.
In conclusion, Cablivi is a prescription medication used to treat aTTP. As a healthcare professional, it is important to have a thorough understanding of Cablivi’s prescribing information, including its indication, dosage, contraindications, adverse reactions, drug interactions, and use in pregnancy and lactation. By following these guidelines, you can help ensure safe and effective treatment for your patients with aTTP.
